CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS

The side effect of the drugs used in treating chronic obstructive pulmonary disease can hamper the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information, there are some severe side effects associated with the drugs used in the treatment of the chronic obstructive pulmonary disease like bruising, oral infections, and hoarseness. These medications are useful for people with frequent exacerbations of chronic obstructive pulmonary disease. Examples of inhaled steroids include Fluticasone (Flovent HFA). Respiratory infections are observed in people with COPD who are more likely to catch colds, flu and pneumonia. Chronic obstructive pulmonary disease can cause many complications like high blood pressure in lung arteries, depression, heart problems, and lung cancer in some cases.

Market Opportunity – Increasing Collaborations among Key Market Players

For instance, in March 2023, UC Davis Health, an health center in the U.S., and Propeller Health announced a new collaboration that will offer personalized treatment for high-risk patients with asthma and chronic obstructive pulmonary disease (COPD). UC Davis Health will provide the Propeller Health an remote monitoring program to eligible patients. It includes sensors, a mobile app, web portal, and personalized support. The sensors attach to a patient’s inhaler to capture unique signals that record events, such as medication usage or respiration. This data will be transmitted to UC Davis Health’s electronic health record system to support patient enrollment and remote patient monitoring via single sign-on. The remote monitoring system may be expanded to patients in other University of California health systems.